The recent finding that employees of Glaxo SmithKline (GSK) provided funds to physicians in China to influence their prescribing has made this a topic of concern in China as well as in many other countries. This article describes the situation of physician payments and bribes in the US and China, and discusses the issues related to proprietary organizations such as pharmaceutical companies providing payments to physicians to influence their prescribing of the company’s products.
